Document Detail


Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports.
MedLine Citation:
PMID:  16640745     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Rituximab is a chimeric monoclonal antibody specific for human CD20 that causes selective transient depletion of the CD20+ B-cell subpopulation. We report the first case of systemic lupus erythematosus (SLE) pneumonitis resistant to conventional treatments that responded well to rituximab and review current reports on the use of rituximab in SLE.
Authors:
S W Lim; D Gillis; W Smith; P Hissaria; H Greville; C A Peh
Related Documents :
24840285 - Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases...
6710265 - Lupus erythematosus with erythema multiforme (rowell's syndrome). a case report.
10773915 - Systemic lupus erythematosus and sickle cell disease.
16807995 - An unusual case with membranous lipodystrophy in a hypertensive patient with transepide...
8458145 - Salmonella typhi osteomyelitis in a nonsickle cell patient. a case report.
22878365 - Mucinous nevus with fat: an unusual case report and literature review.
Publication Detail:
Type:  Case Reports; Journal Article; Review    
Journal Detail:
Title:  Internal medicine journal     Volume:  36     ISSN:  1445-5994     ISO Abbreviation:  Intern Med J     Publication Date:  2006 Apr 
Date Detail:
Created Date:  2006-04-27     Completed Date:  2006-07-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101092952     Medline TA:  Intern Med J     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  260-2     Citation Subset:  IM    
Affiliation:
Immunology Department, Royal Adelaide Hospital, Adelaide, South Australia, Australia. slim1@mail.rah.sa.gov.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antibodies, Monoclonal / therapeutic use*
Exercise Tolerance / drug effects
Female
Humans
Immunologic Factors / therapeutic use*
Lupus Erythematosus, Systemic / complications,  drug therapy*
Pneumonia / drug therapy*,  etiology
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Immunologic Factors; 0/rituximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Does being against euthanasia legislation equate to being anti-euthanasia?
Next Document:  On the need for probity when physicians interact with industry.